Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Complete Title: A Phase I, First in Human Open Label Study to Evaluate the Safety and Tolerability of TRX103 cell infusion in subjects with hematological malignancies undergoing HLA-mismatched related or unrelated hematopoietic stem cell transplantation (HSCT).
Trial Phase: I
Investigator: Filippo Milano
The purpose of this Phase 1, first in human open-label study is to assess the safety and tolerability of TRX-103 in patients with hematological malignancies undergoing HLA-mismatched related or unrelated hematopoietic stem cell transplantation (HSCT). It is anticipated that up to 36 Subjects will be enrolled during a 18-24 month enrollment period. TRX-103 will be infused one time post HSCT.
Keywords:
- Leukemia, Acute Lymphoblastic (ALL); Leukemia, Acute Myeloid (AML); Hematologic Malignancies; Myelodysplastic Syndromes (MDS); Graft Versus Host Disease (GVHD); Hematopoietic Cell Transplantation (HCT); Leukemia, Chronic Myelomonocytic (CMML); Leukemia, T-Cell, Acute Lymphoblastic
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.